Can a virtual conference feel real?
Do scientists have a say in their benefactors’ business? And what does it take to get remdesivir in the U.S.?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Kate Sheridan joins us for a dispatch from this week’s BIO conference, a huge annual event that has been forced online by the coronavirus pandemic.
Then, we discuss the strange situation brewing at the Chan Zuckerberg Initiative, where a bunch of scientists have signed an open letter decrying their benefactor’s other business, Facebook. Finally, STAT’s Eric Boodman calls in to talk about the lengths patients have to go to get remdesivir, Gilead Sciences’ treatment for Covid-19.
Listen here.
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Kate Sheridan joins us for a dispatch from this week’s BIO conference, a huge annual event that has been forced online by the coronavirus pandemic.
Then, we discuss the strange situation brewing at the Chan Zuckerberg Initiative, where a bunch of scientists have signed an open letter decrying their benefactor’s other business, Facebook. Finally, STAT’s Eric Boodman calls in to talk about the lengths patients have to go to get remdesivir, Gilead Sciences’ treatment for Covid-19.
Listen here.
No hay comentarios:
Publicar un comentario